| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/40-1/250 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | LSH; PASG; SMARCA6; Nbla10143 |
| WB Predicted band size | 97 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human HELLS |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于HELLS抗体的3篇示例文献(注：以下内容为示例，具体文献需根据实际研究补充)：
---
1. **文献名称**：*HELLS (Lsh) is required for DNA methylation and retrotransposon silencing in mouse embryonic stem cells*
**作者**：Myant K, et al.
**摘要**：本研究利用HELLS特异性抗体(如Abcam #ab12345)通过染色质免疫沉淀(ChIP)和Western blot技术，揭示了HELLS蛋白在小鼠胚胎干细胞中调控DNA甲基化和抑制逆转录转座子的关键作用。抗体验证显示HELLS缺失导致全基因组甲基化水平显著下降。
2. **文献名称**：*HELLS interacts with DNA methyltransferases to maintain glioblastoma stem cells*
**作者**：Smith J, et al.
**摘要**：通过免疫组化(IHC)和免疫共沉淀(Co-IP)实验，本研究使用HELLS抗体(Cell Signaling Technology #CST6789)证明HELLS与DNMT3A在胶质母细胞瘤干细胞中相互作用，维持肿瘤干性与表观遗传稳定性。抗体特异性经敲低实验验证。
3. **文献名称**：*Loss of HELLS impairs lymphoid development via dysregulation of pre-B cell receptor signaling*
**作者**：Wang L, et al.
**摘要**：该研究通过流式细胞术和免疫荧光技术(使用Santa Cruz Biotechnology #sc-56789 HELLS抗体)，发现HELLS缺失导致前B细胞受体信号通路异常，揭示其在淋巴细胞发育中的必要性。抗体验证显示HELLS在早期B细胞中高表达。
---
**说明**：以上文献为示例性质，实际研究中需根据具体抗体品牌(如Abcam、CST等)和文献内容调整。建议通过PubMed或Google Scholar以“HELLS antibody”或“Lsh SMARCA6 antibody”为关键词检索最新研究。
HELLS (Helicase, Lymphoid-Specific), also known as LSH (Lymphoid-Specific Helicase) or SMARCA6. is a chromatin-remodeling protein belonging to the SNF2 family of helicases. It plays a critical role in maintaining genome stability, DNA methylation, and heterochromatin organization. HELLS facilitates nucleosome repositioning, enabling access to DNA during replication, repair, and transcriptional regulation. Its dysfunction is linked to developmental disorders, immunodeficiency, and cancer, particularly due to its role in epigenetic silencing and genomic imprinting.
HELLS antibodies are essential tools for studying these mechanisms. They are widely used in techniques like Western blotting, immunofluorescence, and chromatin immunoprecipitation (ChIP) to detect HELLS expression, localization, and interactions. Researchers employ these antibodies to investigate HELLS's involvement in chromatin dynamics, stem cell differentiation, and tumorigenesis. For example, studies reveal HELLS overexpression in various cancers, correlating with poor prognosis, while its deficiency causes ICF syndrome (Immunodeficiency, Centromeric instability, Facial anomalies). Commercial HELLS antibodies are typically raised against specific epitopes, validated for species cross-reactivity (human, mouse, rat), and optimized for experimental reproducibility. Ongoing research focuses on targeting HELLS for epigenetic therapies, emphasizing its biomarker potential in oncology and regenerative medicine.
×
